High-Throughput Screening for Identification of Blood-Brain Barrier Integrity Enhancers: A Drug Repurposing Opportunity to Rectify Vascular Amyloid Toxicity

Abstract

The blood-brain barrier (BBB) is a dynamic interface that maintains brain homeostasis and protects it from free entry of chemicals, toxins, and drugs. The barrier function of the BBB is maintained mainly by capillary endothelial cells that physically separate brain from blood. Several neurological diseases, such as Alzheimer’s disease (AD), are known to disrupt BBB integrity. In this study, a high-throughput screening (HTS) was developed to identify drugs that rectify/protect BBB integrity from vascular amyloid toxicity associated with AD progression. Assessing Lucifer Yellow permeation across in-vitro BBB model composed from mouse brain endothelial cells (bEnd3) grown on 96-well plate inserts was used to screen 1280 compounds of Sigma LOPAC^®1280 library for modulators of bEnd3 monolayer integrity. HTS identified 62 compounds as disruptors, and 50 compounds as enhancers of the endothelial barrier integrity. From these 50 enhancers, 7 FDA approved drugs were identified with EC₅₀ values ranging from 0.76–4.56 μM. Of these 7 drugs, 5 were able to protect bEnd3-based BBB model integrity against amyloid toxicity. Furthermore, to test the translational potential to humans, the 7 drugs were tested for their ability to rectify the disruptive effect of Aβ in the human endothelial cell line hCMEC/D3. Only 3 (etodolac, granisetron, and beclomethasone) out of the 5 effective drugs in the bEnd3-based BBB model demonstrated a promising effect to protect the hCMEC/D3-based BBB model integrity. These drugs are compelling candidates for repurposing as therapeutic agents that could rectify dysfunctional BBB associated with AD.

Keywords

Amyloid-β blood-brain barrier high-throughput screening permeability repurposing

INTRODUCTION

The blood-brain barrier (BBB) is a complex barrier that separates brain from blood. BBB comprises of different cellular components; however, the barrier or gate function of the BBB is provided primarily by the endothelial cells (ECs) lining the brain capillaries [1, 2]. These ECs are anchored to a continuous basement membrane (BM) and connected to each other by tight and adherens junctions (AJ) [3]. Tight junctions (TJ) between adjacent ECs face the luminal side of the BBB and consist of the transmembrane TJ proteins occludin and claudins, junctional adhesion molecules (JAMs), and adaptor molecules that connect TJ proteins to actin cytoskeleton [1, 4]. Similarly, AJ face the abluminal side of the BBB and consist of the transmembrane AJ proteins VE-cadherin and catenin, and adaptor molecules that link AJ proteins to actin cytoskeleton [1, 4]. Thus, sealed ECs monolayer form a restrictive barrier that precludes free movement of substances between blood and brain.

Several lines of evidence implicate that disruption of the BBB may precede, accelerate, or contribute to neuronal dysfunction [5]. Moreover, the compromised BBB is associated with several neurological diseases such as neurodegenerative diseases (e.g., Alzheimer’s disease (AD) and amyotrophic lateral sclerosis) [6, 7], cerebrovascular diseases (e.g., stroke) [8], brain infections (e.g., meningitis) [9], and inflammatory disorders (e.g., multiple sclerosis) [10]. In addition to pathological conditions, many chemicals circulating in the blood could affect the BBB integrity [4]. Some of these chemicals are capable of increasing the BBB permeability while others have the opposite effect, i.e. improving tightness and function of the BBB [4].

In AD, BBB breakdown could range from mild disruption of TJs with enhanced BBB permeability to chronic integrity loss with altered transport of molecules across the BBB, brain hypo-perfusion and inflammatory responses [1]. Several studies have attributed these pathological changes in the BBB to accumulated amyloid-β peptides in the brain of AD patients. Increased levels of soluble Aβ have been shown to affect the BBB-endothelial cells integrity by reducing the expression and re-localization of TJ proteins [11]. In addition, reduction in transporters’ expression and activity in the endothelial cells of human and rodents’ BBB were observed when these cells were exposed to different amyloid preparations [12, 13].

To study the BBB biology and activity, several in vivo, in vitro, and in silico models have been established [14 –16]. In vivo experiments provide the most reliable information on the BBB activity and integrity; however, the complexity of this model renders its use for drug screening and urges the development of more feasible in vitro models for drugs screening [16, 17]. Nowadays, many in vitro models that are established from primary or immortalized ECs are available to study the BBB function [15, 18]. In vitro models assembled from primary ECs isolated from rodents’ brains are usually preferred because they resemble the BBB endothelium characteristics; however, the yield of cell isolation and culturing is very low making this model inappropriate for high-throughput screening (HTS) purposes [16 , 20]. Other types of in vitro models utilize cells of epithelial origin such as MDCK cells; while these cells fulfill some BBB characteristics, they are not similar to the brain endothelium [21]. Thus, immortalized brain ECs are more beneficial over epithelial cells and mimic the BBB more closely [21, 22]. Immortalized brain ECs grown on a porous membrane coated with a substitute of basal lamina is the most widely used model to evaluate the BBB endothelium monolayer integrity [6 , 22]. In this model, ECs form a tight monolayer that could be easily manipulated by chemicals or a disease condition to study their effect on the barrier integrity of the ECs monolayer [23]. Although these models are currently available to investigate the dynamic function of the BBB in normal and pathological states [1 , 24], none of them has been used for the screening of a large number of compounds due to associated cost, reliability, and time constraints [18, 23].

Accordingly, the first intent of this study was to upgrade and optimize a cell-based BBB model for HTS purposes. Following the model optimization to be suited for HTS, a large number of compounds were evaluated for their effect on the barrier integrity of the ECs-based BBB. Findings from the HTS identified two types of compounds; compounds that increase the BBB model permeability by disrupting TJs between ECs, and more vitally, compounds that enhance the TJs between ECs and decrease the BBB model permeability. In addition, among the identified integrity enhancers several FDA-approved drugs were recognized, a finding which is significant for their potential of repurposing to treat or prevent the BBB breakdown caused by amyloid-β in AD. Repurposing of FDA-approved drugs for the treatment of AD is an innovative approach because these drugs are well-studied and evaluated, and thus could be taken forward to clinical trials.

MATERIALS AND METHODS

Materials

Fibronectin from bovine plasma, Lucifer Yellow (LY), and compounds library LOPAC^®1280 were purchased from Sigma-Aldrich (St. Louis, MO). HTS 3 μm polycarbonate membrane transwell 96-well plates and 0.45 μm polyester membrane transwell 24-well plates were purchased from Corning (Corning, NY). Rat-tail collagen type-I, sterile PBS, DMEM medium and penicillin/streptomycin antibiotics were obtained from Gibco (Grand Island, NY). ¹⁴C-inulin ([carboxyl-¹⁴C]-inulin, M.W.: 5000 Da) was purchased from American Radiolabeled Chemicals (St. Louis, MO). The MTT assay was obtained from Trevigen (Gaithersburg, MD). All other chemicals, reagents and supplies were purchased from VWR (West Chester, PA) and Sigma-Aldrich (St. Louis, MO).

Cell culture

The immortalized mouse brain endothelial cell line, bEnd3 was obtained from ATCC (Manassas, VA) and used as a representative model for the BBB endothelium [25, 26]. bEnd3 cells, passage 25–35, were cultured in DMEM supplemented with 10% fetal bovine serum (FBS), penicillin G (100 IU/ml), streptomycin (100 μg/ml), 1% w/v nonessential amino acids, and glutamine 2 mM. Cultures were maintained in a humidified atmosphere (5% CO₂/95% air) at 37°C and media was changed every other day. The human brain endothelial cell line hCMEC/D3 (kindly provided by Dr. P.O. Couraud, Institute Cochin, Paris, France), passage 25–30, were cultured in EBM-2 medium supplemented with 1 ng/ml human basic fibroblast growth factor (Sigma-Aldrich, MO), 10 mM HEPES, 1% chemically defined lipid concentrate (Gibco, NY), 5 μg/ml ascorbic acid, 1.4 μM hydrocortisone, 1% penicillin-streptomycin, and 5% of heat-inactivated FBS “gold”. Cultures were maintained in a humidified atmosphere (5% CO2/95% air) at 37°C.

Establishment of the BBB endothelium model for HTS

bEnd3 cells were plated onto HTS transwell 96-well plate with polycarbonate membrane inserts, 4.26 mm diameter with 3 μm pores size, at a seeding density of 50,000 cells/cm². To achieve optimal barrier integrity of bEnd3 cells, transwell membrane should be coated with basement membrane substitute (BM-substitute). Thus, we compared the barrier function of bEnd3 cells grown on transwells coated with different BM-substitutes, including fibronectin from bovine plasma at concentrations of 30 and 60 μg/ml, rat-tail collagen type-I at concentrations of 150 and 300 μg/ml, or a mixture of fibronectin and collagen (30 and 150 μg/ml, respectively). For coating, 50 μl of BM-substitute diluted in sterile PBS was added to the apical side of each transwell filter. The transwell plate containing the filters was placed in a 37°C, 5% CO₂/95% air incubator for 2 h to form a coat. Before cells seeding, 150 μl fresh media was added to the apical side of each transwell filter, then the total volume of BM solution and media was removed by aspiration. For cell seeding, 50 μl of cell suspension was added to the apical side of each transwell filter and 200 μl of fresh media was added to the basolateral side. Cells were incubated at 37°C, 5% CO₂/95% air for 6 days. At the end of incubation period, barrier function of bEnd3 cells grown on the top of transwell filters coated with different types of BM-substitutes, transwell filters coated with different type of BM-substitutes (without cells), and transwell filters without coat were evaluated by measurement of LY permeation coefficient as described below.

Permeability assay

On the experiment day, the endothelial barrier integrity was evaluated by measuring LY permeation across immortalized mouse and human brain capillary endothelial cell lines. LY is a small, water-soluble molecule that travels across bEnd3 cells monolayer only through passive paracellular diffusion (i.e., through space between cells) [25], therefore, any changes in the tightness of bEnd3 monolayer will affect the permeation of LY. To initiate the transport experiment, 50 μl of transport buffer (141 mM NaCl, 4 mM KCl, 2.8 mM CaCl₂, 1 mM MgSO₄, 10 mM HEPES, and 10 mM D-glucose, pH 7.4) containing 100 μM LY was loaded onto the apical side of each transwell filter. Two hundred microliters of fresh and pre-warmed transport buffer were added to the basolateral side of each transwell filter. The transwell plate was then placed in a 37°C, 5% CO₂/95% air incubator for 1 h. LY concentrations in apical and basolateral compartments were determined by measuring their fluorescence intensities in addition to standards of LY of known concentrations at excitation and emission wavelengths of 485 and 529 nm, respectively (Synergy 2 microplate reader; Biotek, VT). Data acquisition was achieved using Gene5 software (Biotek, VT). Apparent permeation coefficient (Pc) was calculated from the following equation: $Pc (cm / sec) = \frac{V_{b} \times C_{b}}{C_{a} \times A \times T}$ (1) where, V_b is the volume of basolateral side (200 μl), C_b is the concentration of LY ( μM) in the basolateral side, C_a is the concentration of LY ( μM) in the apical side, A is the membrane area (0.143 cm²), and T is the time of transport (3600 sec). In addition, permeability measurements from 1 to 7 days of seeding were analyzed to determine the day on which bEnd3 cells forms the tightest monolayer measured as lowest LY permeation (i.e., day of maximum barrier integrity).

bEnd3 cells growth assay

To monitor the growth of bEnd3 cells on the top of coated transwell membrane, number of viable cells was daily assessed using the MTT assay. MTT assay is based on the reduction of a highly water-soluble tetrazolium dye by mitochondrial dehydrogenase to insoluble purple formazan. MTT assays were performed daily starting on day 1 to day 7 of seeding as described previously [27]. Trans-epithelial electrical resistance (TEER) was also performed and measured using an EVOM epithelial volt-ohmmeter with STX2 electrodes (World Precision Instruments, FL).

Model and assay validation

To validate the barrier function of the optimized bEnd3 monolayer, we compared LY permeation across bEnd3 monolayer grown on top of 3 μm polycarbonate membrane to cells grown on top of 0.45 μm

polyester membrane. Both membranes were coated with 30 μg/ml fibronectin, seeded with 1750 cells per well (seeding density of 50,000 cells/cm²), and allowed to grow for 6 days for tight monolayer formation. LY permeation assay was performed on day 6. Moreover, we validated LY as a marker for paracellular diffusion by comparing its permeation across bEnd3 monolayer to the permeation of ¹⁴C-inulin ([carboxyl-¹⁴C]-inulin, M.W.: 5000 Da). Inulin is a large molecule that has been used as a paracellular permeability marker [28]. For inulin permeation, 50 μl of transport buffer containing 0.05 mM ¹⁴C-inulin was added to the apical chamber, and 200 μl of pre-warmed transport buffer was added to the basolateral chamber. Cells were maintained in a humidified atmosphere (5% CO₂/95% air) at 37°C for 1 h. Fifty microliter aliquots from the apical and basolateral chambers were collected at the end of incubation period. After mixing samples with 1 ml of scintillation cocktail, ¹⁴C-inulin dpm was measured using a Wallac 1414 WinSpectral Liquid Scintillation Counter (PerkinElmer, MA). Concentrations of ¹⁴C-inulin in apical and basolateral side were calculated in dpm/ml. The Pc of ¹⁴C-inulin (cm/sec) was calculated using Equation 1 as described above.

Quality control of the model

To investigate robustness and performance of the optimized bEnd3 monolayer as a BBB model for HTS, the Z^′ factor, signal-to-noise ratios (S/N), and signal-to-background ratios (S/B) were calculated for 30 randomly selected plates performed on ten different days. DMSO (0.1%) was used as negative control, 1.4 M mannitol, and 10 μM hydrocortisone were used as positive controls to evaluate the performance of bEnd3 monolayer in HTS. The Z^′-factor, S/N, and S/B were considered as criteria for data quality and were calculated according to the following equations [29]: $Z^{'} f a c t o r = 1 - \frac{3 * SD hydrocortisone or Mannitol + 3 * SD DMSO control}{|Mean Hydrocortisone or Mannitol - Mean DMSO control|}$ (2) $S / N = \frac{| Mean Hydrocortisone or Mannitol - Mean DMSO control |}{SD DMSO control}$ (3) $S / B = \frac{Mean Hydrocortisone or Mannitol}{Mean DMSO control}$ (4)

Where SD is standard deviation.

Compounds screening

Sigma LOPAC^®1280 library, containing 1280 pharmacologically active compounds with known mechanisms, was used for compounds screening. These compounds were screened for their effects on the barrier integrity of bEnd3 monolayer using the LY permeation assay described above. Compounds were added to the apical side of the transwells on day 5 of seeding after dilution in DMEM to a final concentration of 10 μM. This dilution resulted in a final 0.1% DMSO concentration. Preliminary studies showed that this DMSO concentration has no effect on the integrity of bEnd3 monolayer, and were included as a negative control. The concentration 10 μM was selected for screening based on available studies [30, 31]. Each compound was tested in 6 replicates. Plates were incubated with drugs for 24 h at 37°C, 5% CO₂/95% air. At the end of treatment period (day 6 post-seeding), LY permeation assay was performed, and the Pc was calculated as described above. For each compound, the average Pc of the 6 replicates was normalized to a z-score based on the median and median absolute deviation (MAD) values of each plate. The z-score was calculated from the following equation [32]:

$Z - score = \frac{x - X}{MAD}$ (5) where x is the mean of the Pc after treatment with each compound, X is the median across all compounds in the plate without controls, and MAD is median absolute deviation across all compounds in the plate [MAD = 1.4826 × X × (|x - X|)]. A compound with z-score >3 (i.e. increased permeability by more than 3 MADs) was considered a “disruptor” to bEnd3 monolayer integrity as it significantly increased LY permeation, while a compound with z-score < –2 (i.e. reduced permeability by more than 2 MADs) was considered as “enhancer” or a “hit” and was further selected for secondary concentration-dependent screening. Hits that are FDA approved drugs and demonstrated reduced Pc were selected for secondary confirmatory screening. In the secondary screen, hits were first tested in a 6-point concentration-response series (0.75–10 μM) using the LY permeation assay, then confirmed hits were re-tested in a 10-point concentration-response studies ranging from 0.065 to 20 μM to calculate the EC₅₀ value for each compound. All Curve fittings were performed using GraphPad Prism (Version5, GraphPad Software, CA) software.

Western blots analyses of tight junction protein claudin-5

bEnd3 cells (50,000 cells/cm²) were seeded in 10 mm dishes for western blot analysis and allowed to grow to 70% confluency before treatment with drugs in a humidified atmosphere (5% CO₂/95% air) at 37°C. On day 5 post-seeding, cells were treated with 10 μM of control and hit compounds for 24 h. At the end of treatment period, cells were lysed with RIPA buffer containing complete mammalian protease inhibitors. 25 μg of cellular protein was resolved on 8% Bis-tris gels and electrotransferred onto 0.45 μm nitrocellulose membrane. Membranes were blocked with 2% BSA and incubated overnight with monoclonal antibody for claudin-5 (H-52; Santa Cruz Biotechnology, Inc.; TX) or actin (Santa Cruz) at dilutions 1:200. For antigen detection, HRP-labeled secondary IgG antibody for claudin-5 (anti-rabbit) and actin (anti-rabbit) (Santa Cruz) at 1:2000 dilutions were used. The bands were visualized using a SuperSignal West Femto detection kit (Thermo Scientific, IL). Quantitative analysis of the immunoreactive bands was performed using Li-Core luminescent image analyzer (LI-COR Biotechnology, NE) and band intensity was measured by densitometric analysis. Three independent western blotting experiments were carried out for each treatment group.

Immunostaining of the tight junction claudin-5

On day 6, cells treated on previous day with hit compounds were pre-fixed with 1:1 ratio of ice cold PBS and 4% formaldehyde for 5 min, followed by washing. Cells were then fixed with 4% formaldehyde/PBS for 10 min, permeabilized with 0.2% TritonX-100 for 10 min, blocked with 10% BSA containing 0.01% TritonX-100 for 1 h, then washed with PBS. Claudin-5 was visualized using the mouse monoclonal antibody claudin-5-Alexa Fluor 488 (Thermo Scientific, MA) added to the cells and kept overnight at 4°C; nuclear staining was performed with 4,6-diamidino-2-phenylindole (DAPI) for 10 min. Cells were observed using Nikon Eclipse Ti-S inverted fluorescence microscope (Norcross, GA) at a total magnification of 20X. Fluorescence signals of claudin-5 were assessed using ImageJ software. The fold change of claudin-5 staining was determined by dividing the fluorescence signal of claudin-5 in drug treated cells by claudin-5 signal of DMSO treated cells (control). Each fluorescence signal was calculated by taking the average signals of 15 cells per image per treatment group. Three independent experiments were carried out for each treatment group.

Effect of hit FDA compounds on compromised bEnd3 cell-based BBB model by amyloid-β

Solutions of synthetic amyloid-β (Aβ) peptides including Aβ₄₀, Aβ₄₂ and Aβ₄₂ oligomers were prepared and characterized as described previously [33]. Aβ mixtures were prepared by mixing Aβ₄₀ monomers (200 nM) and Aβ₄₂ oligomers (100 nM). On day 5 of seeding, Aβ mixture was added to the basolateral side of the transwells and hit compounds were added to the apical side (each at 10 μM). 24 h later the LY permeation assay was performed as described above to monitor the ability of hit compounds to rectify the BBB model tightness compromised by Aβ mixture.

Effect of hit FDA compounds on rectifying the disruptive effect of Aβ mixture in hCMEC/D3 cell-based BBB model

The translational potential of findings from the mouse endothelial cells bEnd3 was tested using the human brain endothelial cell line hCMEC/D3. hCMEC/D3 cells were grown on inserts to form a monolayer as described previously by us [33 –35]. On day 5, cells were treated for 24 h with control media or mixture of 100 nM monomeric Aβ₄₀ and 50 nM Aβ₄₂ oligomers added to the basolateral side of the transwells and hit compounds added to the apical side (each at 10 μM) as described previously [33]. On the next day, LY permeation assay was performed as described above to monitor the ability of compounds to rectify cells monolayer tightness compromised by Aβ mixture.

Statistical analysis

Unless otherwise indicated, the data were expressed as mean ± SEM. The experimental results were statistically analyzed for significant difference using two-tailed Student’s t-test for two groups, and one-way analysis of variance (ANOVA) for more than two groups’ analysis. Values of p < 0.05 were considered statistically significant.

RESULTS

A schematic presentation of the model and its application is demonstrated in Scheme 1.

Coating optimization

For optimal growth and to form a tight monolayer that could simulate the BBB endothelial function, bEnd3 cells should be grown on the top of supporting membrane coated with a BM-substitute. Thus, to find a suitable BM-substitute that offers high restriction for paracellular diffusion in the presence of a cell monolayer while providing weak barrier properties in the absence of cells, we have screened 2 types of BM-substitutes. Fibronectin and rat-tail collagen type I were investigated as both are commonly used BM-substitutes that support the growth of bEnd3 cells [36, 37]. In the absence of cells, collagen (300 μg/ml), fibronectin (60 μg/ml), and a mixture of collagen (150 μg/ml) and fibronectin (30 μg/ml) formed a barrier to LY permeation, which is based on the measurement of LY Pc as a paracellular diffusion marker (Fig. 1a) [26]. On the other hand, LY permeation across wells coated with collagen (150 μg/ml) or fibronectin (30 μg/ml) showed comparable LY permeation to that of uncoated wells indicative that both coatings did not form a barrier restricting LY permeation (Fig. 1a). In the presence of cells, among both, fibronectin at 30 μg/ml significantly reduced the Pc of LY (Pc = 3.5×10^–5 ± 2.7×10^–6 cm/s; p < 0.001) compared to collagen at 150 μg/ml (Pc of 7.9×10^–5 ± 1.8×10^–6 cm/s) (Fig. 1a). Based on these results, 30 μg/ml fibronectin for coating was selected and used in all subsequent experiments.

Permeability, resistance, and growth assessment of bEnd3 monolayer

For selection of the optimal day for compounds treatment and permeability screening, we daily monitored the growth of bEnd3 cells and LY permeation up to 7 days post-seeding. Figure 1b shows a linear increase in the number of cells from day 1 to 3 post-seeding (doubling time is 24 h), reaching a plateau on days 3–6 where cell number did not significantly increase, indicating the formation of confluent monolayer. Consistent with the cell growth pattern, the monolayer was leaky on day 1 as demonstrated by the LY permeation coefficient values (Fig. 1b), which gradually decreased with time up to day 4 demonstrating the formation of a tight monolayer. LY permeation coefficient remained almost constant between days 4–6 post-seeding (Pc ∼ 4.0×10^–5 cm/sec) indicative of tight junction formation restricting the paracellular permeation of LY (Fig. 1b). On day 7, the reduction in cell number was correlated with the increase in LY permeation indicating initiation of cell de-attachment or death. According to these results, all consequent studies were performed on day 5 for compounds treatment for 24 h followed by LY permeation assay on day 6. In addition and consistent with cell growth and LY permeation behavior, the monolayer resistance monitored by TEER measurements demonstrated a TEER value of ∼35 Ω.cm² on days 5 and 6 post-seeding, which is consistent with our previous studies observed with intact monolayer [33 –35].

Model validation

To validate the barrier function of the in vitro BBB model, LY permeation across bEnd3 monolayer grown on top of 3 μm polycarbonate or 0.45 μm polyester transwell inserts were compared. Polyester membrane with 0.45 μm pore size is a well-established supporting membrane that has been used by many investigators to establish tight endothelial cell monolayer for drug permeability studies [22, 38]; however, this type of membrane is costly for HTS. Our results showed comparable LY Pc values between the two membrane types (Fig. 2a). Moreover, we optimized the use of LY as a marker for paracellular permeability by comparing its permeation coefficient to that of inulin. Our result showed that inulin has significantly lower permeation coefficient than LY (P_c = 3.8×10^–6 ± 4.3×10^–7 versus 3.5×10^–5 ± 1.5×10^–6 cm/s, respectively; Fig. 2b). However, both paracellular permeation markers showed similar pattern in the absence or presence of bEnd3 monolayer; therefore, LY was selected as a paracellular marker for subsequent studies due to its feasibility and practicality over the use of radioactive inulin.

Quality control of established model for HTS

To evaluate the model performance for HTS of compounds, Z^′ factor, signal-to-noise (S/N) and signal-to-background (S/B) ratios were calculated from 30 representative plates (Fig. 3). The Z^′ factor serves as an indicator of assay quality and takes into account the variability in samples data [29]. For cell-based assays, a Z^′ value of 0.5 is an acceptable measure with favorable assay quality. The S/N and S/B are measures for the ability of the system to differentiate between positive and negative controls [29]. In this study, we used this model to identify two types of compounds: compounds that increase LY permeation by disrupting the integrity of bEnd3 monolayer, and compounds that decrease LY permeation by enhancing bEnd3 monolayer integrity. To evaluate the model performance and its ability to identify compounds that increase LY permeation, mannitol (1.4 M) was used as a positive control for compounds that disrupt the integrity of bEnd3 monolayer [39]. The model demonstrated excellent performance to identify disruptors with a Z^′ factor above 0.5 and high S/N and S/B ratios across 30 independent plates (Fig. 3). On the other hand, hydrocortisone (10 μM) was used as a positive control for compounds that enhance integrity and barrier function of bEnd3 monolayer, as it is known to improve tightness of endothelial monolayer by enhancing the expression of TJs proteins [40, 41]. The Z^′ factor determined with hydrocortisone was 0.3 ± 0.11 with lower S/N and S/B ratios compared to those with mannitol (Fig. 3).

Screening of LOPAC^®1280 library

The model was then used to screen Sigma LOPAC^®1280 library comprising of 1280 compounds for enhancers of the in vitro BBB endothelium model tightness. All compounds were tested at concentration of 10 μM in 6 replicates. The apparent Pc was converted to z-score for each screened compound (Fig. 3). In each plate, normalized LY Pc for most compounds followed a normal distributioncentered on the plate median. Using the cut-off criteria for disruptors and enhancers, we could identify 62 compounds as disruptors with z-score greater than 3 MADs from plate median, and 50 compounds as enhancers with z-score less than –2. Out of the 50 compounds that were able to enhance bEnd3 monolayer integrity, there were 10 FDA approved drugs that are in clinical use. In order to assess repurposing opportunities, the effect of these FDA approved drugs on the monolayer integrity was further tested by performing a 6-point concentration-response studies, from which 7 drugs were emerged as hits, while the remaining drugs were excluded from further screening due to their lack of concentration-dependent change in LY permeation (Supplementary Figure 1). The selected 7 hits were then validated in 10-point concentration-response studies in the range 0.065–20 μM to calculate their EC₅₀ (Table 1). As these tested drugs were toxic to the cells at the concentration 20 μM, the EC₅₀ was estimated from the concentration range 0.065–15 μM. The 7 drugs showed a sigmoidal concentration-response reduction in LY permeation across the bEnd3 monolayer with EC₅₀ values ranging from 0.76–4.56 μM (Fig. 4 and Table 1). On the other hand, the primary screen has identified 62 compounds that increased LY permeation across bEnd3 monolayer indicating a disruption in its integrity. Table 2 shows 10 FDA approved drugs that were identified as disruptors when tested at 10 μM concentration.

Effect of hit FDA-approved drugs on claudin-5 expression

Hit FDA drugs were further investigated for potential mechanisms by which these drugs enhanced the BBB model integrity. For this, expression of the tight junction protein claudin-5 was evaluated by immunocytochemistry and western blot. Claudin-5 was specifically evaluated as previous studies have shown hydrocortisone (the positive control used in the current study) to enhance BBB tightness via up-regulation of claudin-5 expression [40, 41]. The expression and localization of claudin-5 in bEnd3 monolayer using immunocytochemistry analysis demonstrated oxaprozin, etodolac, beclomethasone and candesartan to significantly induce claudin-5 expression by 1.6- to 2.1-fold (p < 0.05, Fig. 5a). Similarly, western blot analysis showed tested compounds to increase claudin-5 expression by 15–40% with the highest and significant increase observed with the drugs oxaprozin, etodolac, and beclomethasone when compared to DMSO treated cells (p < 0.05, Fig. 5b).

Protective effect of hit FDA drugs against amyloid vascular toxicity in bEnd3 cells

We evaluated the potential of the hit FDA drugs to improve and rectify the disruptive effect of Aβ mixture. This study was performed based on our previous report [33]. As shown in Fig. 6a, the addition of Aβ mixture (200 nM Aβ₄₀ monomers and 100 nM Aβ₄₂ oligomers) to the basolateral side for 24 h caused a significant increase in LY permeation by 45% compared to control treated cells (p < 0.05). Simultaneous treatment with the hit FDA drugs demonstrated that all drugs, except tomoxetine and pancuronium, rectify the disruptive effect of Aβ mixture to levels comparable to those of control (p < 0.05, Fig. 6a). Pancuronium showed a trend toward reduction; however, the effect was not statistically significant from that of Aβ mixture only treated cells (p > 0.05).

Hit FDA drugs have deferential effect against amyloid vascular toxicity in hCMEC/D3 cells

To evaluate whether the protective effect of hit FDA drugs observed in bEnd3 could be extended to humans, these drugs were tested for their potential to rectify the toxic effect of Aβ mixture (100 nM Aβ₄₀ monomers and 50 nM Aβ₄₂ oligomers) in hCMEC/D3. As shown in Fig. 6b, 24 h treatment with the hit FDA drugs demonstrated that only etodolac, granisetron, and beclomethasone significantly reduce the disruptive effect of Aβ mixture on the BBB model integrity.

DISCUSSION

Brain capillaries are characterized by forming the BBB that maintains constant brain homeostasis and protects the brain from free entry of different substances that could interrupt with normal neural activity [5, 42]. Brain ECs, BM, neurons, astrocytes, and pericytes play important role in supporting the normal function of the BBB [4]. Both pericytes, the uniquely positioned cells within the neurovascular unit, and astrocytes, the most abundant glial cells in the brain, significantly contribute to the unique properties of the ECs in forming a tight BBB [43]. Recent studies have suggested the malfunction of pericytes and astrocytes in AD that contribute to the vascular pathology associated with AD [44, 45]. The reason(s) of pericyte loss in AD is not completely understood, and it is yet to be determined whether their degeneration observed in AD is a consequence of risk factors such as stroke [46], diabetes [47], and brain injury [48], or is Aβ-mediated. Several studies have suggested that Aβ accumulation in pericytes could overwhelm its own clearance and cause pericyte degeneration [49, 50]. Besides, reactive astrocytes have been also observed in chronic neurodegenerative lesions and contribute to neuronal as well as vascular pathogenesis in AD [45]. However, while astrocytes, pericytes, and BM play important role in regulating and supporting the BBB integrity and function, only the capillary endothelium forms the physical barrier separating brain from blood [23]. Therefore, in this study, an in vitro ECs-based BBB model was used, first, because ECs are the main cellular component of the BBB that confer the barrier function [42], and second for practicality reasons that allow HTS of large number of compounds.

In this study, a cell-based assay that effectively represents the barrier function of the BBB endothelium was optimized to screen a library of compounds for their effects on the BBB endothelium integrity. This model was able to identify two set of compounds; compounds that disrupt the BBB endothelium integrity, which might contribute to the development of neurological diseases, and compounds that enhance the BBB integrity and thus could be helpful in the treatment of many neurological diseases including AD and cerebral amyloid angiopathy (CAA).

bEnd3 cell line was used to develop the BBB model that is appropriate for HTS because it possesses several features over primary ECs including simple seeding and rapid formation of tight monolayer, characteristics that make it suitable for sensitive and compatible HTS assay. Besides, bEnd3 cells express most of the properties of in vivo brain ECs such as the expression of TJ proteins, transport proteins and receptors, in addition to their ability to form a tight polarized monolayer restricting the paracellular permeability [20, 51]. While several in-vitro BBB models have been recently developed, none of these models was upgraded for HTS [14 –16]. Therefore, the key objectives of this work were first to increase the capacity of available in vitro BBB models for HTS assays, and second to screen a large number of compounds for their effect on integrity of the in vitro BBB model.

Before using the bEnd3 cell-based BBB model for compounds screening, the model was optimized and validated with a series of experiments that aimed to attain maximal barrier integrity for bEnd3 monolayer. Consistent with previous studies, we found that polycarbonate membrane with pore size of 3 μm coated with 30 μg/ml fibronectin as a BM-substitute was optimal to enhance the growth of bEnd3 cells and produce a tight monolayer [20 , 52]. This combination of the cell-based system and the use of 96-well polycarbonate membrane guaranteed low cost, with high sensitivity and HTS capability.

The assay demonstrated an excellent performance to identify disruptors with Z^′ factor >0.5; however, for integrity enhancers, the assay exhibited a smaller separation, but significant, between the negative control and hydrocortisone treatment (Z^′ factors = 0.3 ± 0.11). A Z^′ factor of <0.5 is considered an acceptable value for this HTS performance because hydrocortisone enhanced the barrier function of the already tight monolayer, hence, LY permeation is not expected to largely deviate from the negative control treatment like that observed with disruptors. Hydrocortisone’s enhancement of the barrier function caused 25% reduction in LY permeation coefficient. Moreover, a Z^′ factor of less than 0.5 has been reported with HTS assays that screen for agonists because it depends on the potency of the positive control in use [53]. To increase the confidence of hits selection, we tested each compound in 6 replicates. Increasing number of replicates enhances the assay performance by decreasing the imprecision of the assay (standard error) [54]. The use of 6 replicates for each compound decreased the imprecision of our assay by ∼63% making this optimized bEnd3 monolayer a powerful tool for hits identification [54]. In further support for the validity of the assay and selection criteria, from the primary screen, among the compounds that have been identified as BBB integrity enhancers was the positive control hydrocortisone, which was blindly tested as part of the library, and among the disruptors was ammonia which is known to have a toxic effect on the BBB [55].

Using the aforementioned optimized model and hit selection analysis, we carried out an initial screen of Sigma LOPAC^®1280 library compounds for their effect on the integrity of bEnd3 monolayer. For hits selection, we used a more sophisticated approach to improve overall confirmation rates that is based on median and median absolute deviation (MAD) of the plate instead of mean and standard deviation [32]. Median and MAD values are resistant to the presence of outliers, and hits selection by the MAD-based method include all the hits that would be selected by the SD-based method with a significant number of additional hits [32]. The results of this screen identified 62 compounds that disrupted the barrier integrity of bEnd3 monolayer, and 50 compounds that enhanced the monolayer integrity. In the current study, the only therapeutic or clinical envision from identification of compounds that disrupt bEnd3 monolayer integrity is to show possible adverse effect of these compounds if they are FDA approved drugs. On the other hand, identifying compounds that enhance the barrier function of the bEnd3 monolayer could have a broad spectrum of clinical applications in treatment or prevention of BBB breakdown associated with different neurological diseases such as AD and CAA [4 , 23]. Among the 50 compounds that enhanced the bEnd3 monolayer integrity 10 hits were FDA approved drugs. Seven of these hit FDA drugs were further selected for the secondary screening and EC₅₀ calculation. Then, these drugs were tested for their protective effect against Aβ toxicity. Previous reports suggested repurposing of FDA approved drugs as an efficient drug discovery strategy to identify drugs that could be used in the treatment of neurological diseases including AD [56 –58]. This strategy offers an alternative and cost-effective drug development approach with potential to identify new treatments in a fraction of the time required to develop a treatment from scratch [56].

Available evidences from biochemical, genetic and animal studies implicate Aβ as a pathogenic peptide in AD [59]. The amyloid cascade hypothesis stated that AD is caused by an imbalance between Aβ production and clearance, resulting in an increased amount of Aβ in various forms such as monomers, oligomers, insoluble fibrils, and plaques in the CNS [59]. In AD, clearance of Aβ from the brain takes place by three pathways: (a) transport across the BBB [7]; (b) degradation in the brain tissue which is mediated by specific Aβ degrading enzymes or by glial cell uptake and lysosomal degradation [60]; and (c) the bulk flow of the ISF into the cerebrospinal fluid (CSF) [61]. Among the 3 pathways, Aβ transport across the BBB has the highest contribution to the overall brain clearance with estimated clearance of 62% in mice [35]. As a peptide, Aβ has a poor passive membrane permeability and it depends on a transport system to cross the endothelial cells of the BBB [62]. This transport system consists of multiple receptors and transport proteins at the BBB such as the low-density lipoprotein receptor-related protein-1 (LRP1) and P-glycoprotein (P-gp) [63, 64]. In AD, both transport proteins are downregulated and contribute to Aβ cerebral accumulation [13, 33]. While multiple pathological alterations in AD brains could contribute to vascular dysfunction [53 , 65–67], findings from AD patients’ brains and preclinical studies using AD mice models also support the disruptive effect of increased brain levels of Aβ on the integrity and function of the BBB [11 , 68–70]. This breakdown in the BBB integrity was associated with uncontrolled molecular transport and solute exchange [71], and reduced expression and re-localization of TJ proteins [11 , 70]. Accordingly, such alterations in the BBB observed in AD point toward the BBB as a target for therapeutic interventions to improve or rectify the BBB normal activity [34, 72].

In search for such therapeutics, our HTS identified 7 FDA approved drugs that enhanced bEnd3 monolayer integrity and demonstrated a sigmoidal concentration-response curve with low EC₅₀. These drugs were then evaluated for their potential to rectify the BBB breakdown caused by Aβ, similar to that observed in AD. When tested in the bEnd3 cell-based BBB model, the FDA drugs granisetron, candesartan, beclomethasone, etodolac, and oxaprozin demonstrated a significant potential to ameliorate the integrity of the BBB model exposed to Aβ mixture of oligomers and monomers. Interestingly, however, when these hits tested for their translational potential to humans in hCMEC/D3-based BBB model, only etodolac, granisetron, and beclomethasone demonstrated a significant reduction in LY permeation when compared to Aβ mixture treated cells (p < 0.05), suggesting these 3 drugs have the translational potential to rectify the toxic effect of Aβ. In addition, these findings propose species differences; while 5 out of the 7 drugs demonstrated a positive effect in bEnd3 cell-based BBB model, only 3 drugs were able to rectify the disruptive effect of Aβ mixture in hCMEC/D3-BBB model. This difference, however, is not surprising. In a recent study, we reported differences between bEnd3 and hCMEC/D3 cells where the former cell line was metabolically more active than the latter and cleared Aβ species (by degradation) at a higher rate [35].

Granisetron and etodolac belong to drug classes that have demonstrated beneficial effects against AD [74 –81]. Members of the 5-HT3 receptor antagonists, like granisetron, have shown beneficial effect on memory and learning where it prevented age-induced memory loss in mice [74], and attenuated Aβ-induced neurotoxicity in cultured rat cortical neurons [75]. Similarly, when administered to scopolamine-induced memory-impaired mice, granisetron improved spatial recognition memory and fear memory [76]. The NSAID drug etodolac, on the other hand, while studies evaluating its specific effect in AD are not available, studies examined other members of NSAIDs exist. The beneficial effect of NSAIDs in AD remains controversial; however, several epidemiological studies reported the long-term use of NSAIDs is inversely associated with AD that may be modified by APOE genotype [77 –79]. These results were supported by preclinical studies in transgenic mouse models of AD. For example, when tested in 3×Tg-AD [80] and Tg2576 mice [81], ibuprofen reduced Aβ plaque load and Aβ₄₂ levels. But when evaluated for their therapeutic effect against AD in clinical studies, NSAID treatment failed to enhance the cognitive function in AD patients [82 –84]. Further studies are required to explain such inconsistencies and to confirm the effect of NSAIDs in AD. Nonetheless, findings of the current study suggest a positive effect of etodolac against Aβ toxic effect on the BBB in vitro model integrity, an effect that was not previously reported with other NSAID members. For the efficient translation of the current findings, the 2 drugs, granisetron and etodolac, which demonstrated ability to ameliorate and/or protect the mouse and human ECs-based BBB models will be further evaluated in vivo in AD mouse models.

In conclusion, this study offers, for the first time, a cell-based assay that effectively represents the barrier function of the BBB endothelium for high-throughput screening of compounds for their effects on the barrier integrity. Moreover, we were able to identify FDA approved drugs that could enhance and rectify the integrity of endothelial monolayer and protect from amyloid toxicity in both mouse and human derived endothelial cell lines. These drugs, mainly etodolac, granisetron, and beclomethasone, could be further in vivo evaluated for their ability to rectify the BBB function and treatment of many neurological diseases including AD. Finally, results of the current study suggest that pharmacological targeting of the BBB to enhance its function and integrity could potentially help treat and/or hold the progression of Aβ-related disorders AD and CAA.

Footnotes

ACKNOWLEDGMENTS

This research work was funded by an Institutional Development Award (IDeA) from the National Institute of General Medical Sciences of the National Institutes of Health under grant number P20GM103424, by Louisiana Board of Reagent’s Research Competitive Program under grant number LEQSF(2013-16)-RD-A-16, and by National Institute of Neurological Disorders and Stroke under grant number R15NS091934.

Authors’ disclosures available online ().

Appendix

References

Zlokovic

(2008) The blood-brain barrier in health and chronic neurodegenerative disorders. Neuron 57, 178–201.

Banks

(2009) Characteristics of compounds that cross the blood-brain barrier. BMC Neurol 9(Suppl 1), S3.

Hawkins

, Davis

(2005) The blood-brain barrier/neurovascular unit in health and disease. Pharmacol Rev 57, 173–185.

Abbott

, Ronnback

, Hansson

(2006) Astrocyte-endothelial interactions at the blood-brain barrier. Nat Rev Neurosci 7, 41–53.

Rosenberg

(2012) Neurological diseases in relation to the blood-brain barrier. J Cereb Blood Flow Metab 32, 1139–1151.

Zhong

, Deane

, Ali

, Parisi

, Shapovalov

, O’Banion

, Stojanovic

, Sagare

, Boillee

, Cleveland

, Zlokovic

(2008) ALS-causing SOD1 mutants generate vascular changes prior to motor neuron degeneration. Nat Neurosci 11, 420–422.

Bell

, Zlokovic

(2009) Neurovascular mechanisms and blood-brain barrier disorder in Alzheimer’s disease. Acta Neuropathol 118, 103–113.

Yang

, Estrada

, Thompson

, Liu

, Rosenberg

(2007) Matrix metalloproteinase-mediated disruption of tight junction proteins in cerebral vessels is reversed by synthetic matrix metalloproteinase inhibitor in focal ischemia in rat. J Cereb Blood Flow Metab 27, 697–709.

Leppert

, Lindberg

, Kappos

, Leib

(2001) Matrix metalloproteinases: Multifunctional effectors of inflammation in multiple sclerosis and bacterial meningitis. Brain Res Brain Res Rev 36, 249–257.

10.

Henderson

, Barnett

, Parratt

, Prineas

(2009) Multiple sclerosis: Distribution of inflammatory cells in newly forming lesions. Ann Neurol 66, 739–753.

11.

Gonzalez-Velasquez

, Kotarek

, Moss

(2008) Soluble aggregates of the amyloid-beta protein selectively stimulate permeability in human brain microvascular endothelial monolayers. J Neurochem 107, 466–477.

12.

Qosa

, Abuznait

, Hill

, Kaddoumi

(2012) Enhanced brain amyloid-beta clearance by rifampicin and caffeine as a possible protective mechanism against Alzheimer’s disease. J Alzheimers Dis 31, 151–165.

13.

Brenn

, Grube

, Peters

, Fischer

, Jedlitschky

, Kroemer

, Warzok

, Vogelgesang

(2011) Beta-amyloid downregulates MDR1-P-Glycoprotein (Abcb1) expression at the blood-brain barrier in mice. Int J Alzheimers Dis 2011, 690121.

14.

Abbott

, Dolman

, Patabendige

(2008) Assays to predict drug permeation across the blood-brain barrier, and distribution to brain. Curr Drug Metab 9, 901–910.

15.

Wong

, Ye

, Levy

, Rothstein

, Bergles

, Searson

(2013) The blood-brain barrier: An engineering perspective. Front Neuroeng 6, 7.

16.

Geldenhuys

, Allen

, Bloomquist

(2012) Novel models for assessing blood-brain barrier drug permeation. Expert Opin Drug Metab Toxicol 8, 647–653.

17.

Deguchi

, Morimoto

(2001) Application of an in vivo brain microdialysis technique to studies of drug transport across the blood-brain barrier. Curr Drug Metab 2, 411–423.

18.

Wilhelm

, Fazakas

, Krizbai

(2011) In vitro models of the blood-brain barrier. Acta Neurobiol Exp (Wars) 71, 113–128.

19.

Steiner

, Coisne

, Engelhardt

, Lyck

(2011) Comparison of immortalized bEnd5 and primary mouse brain microvascular endothelial cells as in vitro blood-brain barrier models for the study of T cell extravasation. J Cereb Blood Flow Metab 31, 315–327 .

20.

Brown

, Morris

, O’Neil

(2007) Tight junction protein expression and barrier properties of immortalized mouse brain microvessel endothelial cells. Brain Res 1130, 17–30.

21.

Hellinger

, Veszelka

, Toth

, Walter

, Kittel

, Bakk

, Tihanyi

, Hada

, Nakagawa

, Duy

, Niwa

, Deli

, Vastag

(2012) Comparison of brain capillary endothelial cell-based and epithelial (MDCK-MDR1, Caco-2, and VB-Caco-2) cell-based surrogate blood-brain barrier penetration models. Eur J Pharm Biopharm 82, 340–351.

22.

Weksler

, Subileau

, Perriere

, Charneau

, Holloway

, Leveque

, Tricoire-Leignel

, Nicotra

, Bourdoulous

, Turowski

, Male

, Roux

, Greenwood

, Romero

, Couraud

(2005) Blood-brain barrier-specific properties of a human adult brain endothelial cell line. FASEB J 19, 1872–1874.

23.

Cecchelli

, Berezowski

, Lundquist

, Culot

, Renftel

, Dehouck

, Fenart

(2007) Modelling of the blood-brain barrier in drug discovery and development. Nat Rev Drug Discov 6, 650–661.

24.

Zehendner

, Librizzi

, de Curtis

, Kuhlmann

, Luhmann

(2011) Caspase-3 contributes to ZO-1 and Cl-5 tight-junction disruption in rapid anoxic neurovascular unit damage. PLoS One 6, e16760.

25.

Omidi

, Campbell

, Barar

, Connell

, Akhtar

, Gumbleton

(2003) Evaluation of the immortalised mouse brain capillary endothelial cell line, b. End3, as an in vitro blood-brain barrier model for drug uptake and transport studies. Brain Res 990, 95–112.

26.

Eigenmann

, Xue

, Kim

, Moses

, Hamburger

, Oufir

(2013) Comparative study of four immortalized human brain capillary endothelial cell lines, hCMEC/D3, hBMEC, TY10, and BB19, and optimization of culture conditions, for an in vitro blood-brain barrier model for drug permeability studies. Fluids Barriers CNS 10, 33.

27.

Cooray

, Shahi

, Cahn

, van Veen

, Hladky

, Barrand

(2006) Modulation of p-glycoprotein and breast cancer resistance protein by some prescribed corticosteroids. Eur J Pharmacol 531, 25–33.

28.

Stamatovic

, Dimitrijevic

, Keep

, Andjelkovic

(2006) Protein kinase Calpha-RhoA cross-talk in CCL2-induced alterations in brain endothelial permeability. J Biol Chem 281, 8379–8388.

29.

Zhang

, Chung

, Oldenburg

(1999) A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J Biomol Screen 4, 67–73.

30.

(2010) Assay development: Fundamentals and practices, Wiley, Hoboken, NJ.

31.

Varma

, Lo

, Stockwell

(2011) High-throughput and high-content screening for Huntington’s disease therapeutics. In Neurobiology of Huntington’s disease: Applications to drug discovery, Lo

, Hughes

, eds., CRC Press, Boca Raton.

32.

Chung

, Zhang

, Kreamer

, Locco

, Kuan

, Bartz

, Linsley

, Ferrer

, Strulovici

(2008) Median absolute deviation to improve hit selection for genome-scale RNAi screens. J Biomol Screen 13, 149–158.

33.

Qosa

, LeVine

3rd , Keller

, Kaddoumi

(2014) Mixed oligomers and monomeric amyloid-beta disrupts endothelial cells integrity and reduces monomeric amyloid-beta transport across hCMEC/D3 cell line as an in vitro blood-brain barrier model. Biochim Biophys Acta 1842, 1806–1815.

34.

Qosa

, Batarseh

, Mohyeldin

, El Sayed

, Keller

, Kaddoumi

(2015) Oleocanthal enhances amyloid-beta clearance from the brains of TgSwDI mice and in vitro across a human blood-brain barrier model. ACS Chem Neurosci 6, 1849–1859.

35.

Qosa

, Abuasal

, Romero

, Weksler

, Couraud

, Keller

, Kaddoumi

(2014) Differences in amyloid-beta clearance across mouse and human blood-brain barrier models: Kinetic analysis and mechanistic modeling. Neuropharmacology 79, 668–678.

36.

Hartmann

, Zozulya

, Wegener

, Galla

(2007) The impact of glia-derived extracellular matrices on the barrier function of cerebral endothelial cells: An in vitro study. Exp Cell Res 313, 1318–1325.

37.

Tilling

, Engelbertz

, Decker

, Korte

, Huwel

, Galla

(2002) Expression and adhesive properties of basement membrane proteins in cerebral capillary endothelial cell cultures. Cell Tissue Res 310, 19–29.

38.

Wuest

, Wing

, Lee

(2013) Membrane configuration optimization for a murine in vitro blood-brain barrier model. J Neurosci Methods 212, 211–221.

39.

Hulper

, Veszelka

, Walter

, Wolburg

, Fallier-Becker

, Piontek

, Blasig

, Lakomek

, Kugler

, Deli

(2013) Acute effects of short-chain alkylglycerols on blood-brain barrier properties of cultured brain endothelial cells. Br J Pharmacol 169, 1561–1573.

40.

Kashiwamura

, Sano

, Abe

, Shimizu

, Haruki

, Maeda

, Kawai

, Kanda

(2011) Hydrocortisone enhances the function of the blood-nerve barrier through the up-regulation of claudin-5. Neurochem Res 36, 849–855.

41.

Forster

, Burek

, Romero

, Weksler

, Couraud

, Drenckhahn

(2008) Differential effects of hydrocortisone and TNFalpha on tight junction proteins in an in vitro model of the human blood-brain barrier. J Physiol 586, 1937–1949.

42.

Abbott

, Patabendige

, Dolman

, Yusof

, Begley

(2010) Structure and function of the blood-brain barrier. Neurobiol Dis 37, 13–25.

43.

Winkler

, Bell

, Zlokovic

(2011) Central nervous system pericytes in health and disease. Nat Neurosci 14, 1398–1405.

44.

Bell

, Winkler

, Sagare

, Singh

, LaRue

, Deane

, Zlokovic

(2010) Pericytes control key neurovascular functions and neuronal phenotype in the adult brain and during brain aging. Neuron 68, 409–427.

45.

Sofroniew

, Vinters

(2010) Astrocytes: Biology and pathology. Acta Neuropathol 119, 7–35.

46.

Fernández-Klett

, Potas

, Hilpert

, Blazej

, Radke

, Huck

, Engel

, Stenzel

, Genové

, Priller

(2013) Early loss of pericytes and perivascular stromal cell-induced scar formation after stroke. J Cereb Blood Flow Metab 33, 428–439.

47.

Price

, Eranki

, Banks

, Ercal

, Shah

(2012) Topiramate treatment protects blood-brain barrier pericytes from hyperglycemia-induced oxidative damage in diabetic mice. Endocrinology 153, 362–372.

48.

Dore-Duffy

, Owen

, Balabanov

, Murphy

, Beaumont

, Rafols

(2000) Pericyte migration from the vascular wall in response to traumatic brain injury. Microvasc Res 60, 55–69.

49.

Wilhelmus

, Otte-Holler

, van Triel

, Veerhuis

, Maat-Schieman

, Bu

, de Waal

, Verbeek

(2007) Lipoprotein receptor-related protein-1 mediates amyloid-beta-mediated cell death of cerebrovascular cells. Am J Pathol 171, 1989–1999.

50.

Sagare

, Bell

, Zhao

, Ma

, Winkler

, Ramanathan

, Zlokovic

(2013) Pericyte loss influences Alzheimer-like neurodegeneration in mice. Nat Commun 4, 2932.

51.

Watanabe

, Dohgu

, Takata

, Nishioku

, Nakashima

, Futagami

, Yamauchi

, Kataoka

(2013) Paracellular barrier and tight junction protein expression in the immortalized brain endothelial cell lines bEND.3, bEND.5 and mouse brain endothelial cell 4. Biol Pharm Bull 36, 492–495.

52.

Yuan

, Li

, Gil

, Lowe

, Fu

(2010) Effect of surface charge of immortalized mouse cerebral endothelial cell monolayer on transport of charged solutes. Ann Biomed Eng 38, 1463–1472.

53.

, Arumugam

, Woo

, Park

, Tang

, Mughal

, Hyun

, Park

, Choi

, Gwon

, Camandola

, Cheng

, Cai

, Song

, Markesbery

, Mattson

(2010) Evidence that gamma-secretase mediates oxidative stress-induced beta-secretase expression in Alzheimer’s disease. Neurobiol Aging 31, 917–925.

54.

Malo

, Hanley

, Cerquozzi

, Pelletier

, Nadon

(2006) Statistical practice in high-throughput screening data analysis. Nat Biotechnol 24, 167–175.

55.

McClung

, Sloan

, Powers

, Merola

, Murray

, Kerzner

, Pollack

(1990) Early changes in the permeability of the blood-brain barrier produced by toxins associated with liver failure. Pediatr Res 28, 227–231.

56.

Appleby

, Cummings

(2013) Discovering new treatments for Alzheimer’s disease by repurposing approved medications. Curr Top Med Chem 13, 2306–2327.

57.

Corbett

, Ballard

(2013) Is a potential Alzheimer’s therapy already in use for other conditions? Can medications for hypertension, diabetes and acne help with the symptoms?. Expert Opin Investig Drugs 22, 941–943.

58.

Shehata

, Ballard

, Casper

, Hennings

, Cressman

, Ebbini

(2014) High-intensity focused ultrasound for potential treatment of polycystic ovary syndrome: Toward a noninvasive surgery. Fertil Steril 101, 545–551.

59.

Hardy

(2009) The amyloid hypothesis for Alzheimer’s disease: A critical reappraisal. J Neurochem 110, 1129–1134.

60.

Iwata

, Tsubuki

, Takaki

, Watanabe

, Sekiguchi

, Hosoki

, Kawashima-Morishima

, Lee

, Hama

, Sekine-Aizawa

, Saido

(2000) Identification of the major Abeta1-42-degrading catabolic pathway in brain parenchyma: Suppression leads to biochemical and pathological deposition. Nat Med 6, 143–150.

61.

Silverberg

, Mayo

, Saul

, Rubenstein

, McGuire

(2003) Alzheimer’s disease, normal-pressure hydrocephalus, and senescent changes in CSF circulatory physiology: A hypothesis. Lancet Neurol 2, 506–511.

62.

Zlokovic

, Yamada

, Holtzman

, Ghiso

, Frangione

(2000) Clearance of amyloid beta-peptide from brain: Transport or metabolism?. Nat Med 6, 718–719.

63.

Cirrito

, Deane

, Fagan

, Spinner

, Parsadanian

, Finn

, Jiang

, Prior

, Sagare

, Bales

, Paul

, Zlokovic

, Piwnica-Worms

, Holtzman

(2005) P-glycoprotein deficiency at the blood-brain barrier increases amyloid-beta deposition in an Alzheimer disease mouse model. J Clin Invest 115, 3285–3290.

64.

Shibata

, Yamada

, Kumar

, Calero

, Bading

, Frangione

, Holtzman

, Miller

, Strickland

, Ghiso

, Zlokovic

(2000) Clearance of Alzheimer’s amyloid-ss(1-40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier. J Clin Invest 106, 1489–1499.

65.

Giannoni

, Arango-Lievano

, Neves

, Rousset

, Baranger

, Rivera

, Jeanneteau

, Claeysen

, Marchi

(2016) Cerebrovascular pathology during the progression of experimental Alzheimer’s disease. Neurobiol Dis 88, 107–117.

66.

Park

, Zhou

, Pistick

, El Jamal

, Younkin

, Pierce

, Arreguin

, Anrather

, Younkin

, Carlson

, McEwen

, Iadecola

(2013) Innate immunity receptor CD36 promotes cerebral amyloid angiopathy. Proc Natl Acad Sci U S A 110, 3089–3094.

67.

Paul

, Strickland

, Melchor

(2007) Fibrin deposition accelerates neurovascular damage and neuroinflammation in mouse models of Alzheimer’s disease. J Exp Med 204, 1999–2008.

68.

Carrano

, Hoozemans

, van der Vies

, Rozemuller

, van Horssen

, de Vries

(2011) Amyloid Beta induces oxidative stress-mediated blood-brain barrier changes in capillary amyloid angiopathy. Antioxid Redox Signal 15, 1167–1178.

69.

Hartz

, Bauer

, Soldner

, Wolf

, Boy

, Backhaus

, Mihaljevic

, Bogdahn

, Klunemann

, Schuierer

, Schlachetzki

(2012) Amyloid-beta contributes to blood-brain barrier leakage in transgenic human amyloid precursor protein mice and in humans with cerebral amyloid angiopathy. Stroke 43, 514–523.

70.

Tai

, Holloway

, Male

, Loughlin

, Romero

(2010) Amyloid-beta-induced occludin down-regulation and increased permeability in human brain endothelial cells is mediated by MAPK activation. J Cell Mol Med 14, 1101–1112.

71.

Zlokovic

(2011) Neurovascular pathways to neurodegeneration in Alzheimer’s disease and other disorders. Nat Rev Neurosci 12, 723–738.

72.

Dorr

, Sahota

, Chinta

, Brown

, Lai

, Ma

, Hawkes

, McLaurin

, Stefanovic

(2012) Amyloid-beta-dependent compromise of microvascular structure and function in a model of Alzheimer’s disease. Brain 135, 3039–3050.

73.

Mawuenyega

, Sigurdson

, Ovod

, Munsell

, Kasten

, Morris

, Yarasheski

, Bateman

(2010) Decreased clearance of CNS beta-amyloid in Alzheimer’s disease. Scienc 330, 1774.

74.

Chugh

, Saha

, Sankaranarayanan

, Sharma

(1991) Memory enhancing effects of granisetron (BRL 43694) in a passive avoidance task. Eur J Pharmacol 203, 121–123.

75.

Ju Yeon

Ban

, Yeon

Hee

, Seong (2005) Blockade of 5-HT(3) receptor with MDL 72222 and Y 25130 reduces beta-amyloid protein (25-35)-induced neurotoxicity in cultured rat cortical neurons. Eur J Pharmacol 520, 12–21.

76.

Javadi-Paydar

, Zakeri

, Norouzi

, Rastegar

, Mirazi

, Dehpour

(2012) Involvement of nitric oxide in granisetron improving effect on scopolamine-induced memory impairment in mice. Brain Res 1429, 61–71.

77.

in t’ Veld

, Ruitenberg

, Hofman

, Launer

, van Duijn

, Stijnen

, Breteler

, Stricker

(2001) Nonsteroidal antiinflammatory drugs and the risk of Alzheimer’s disease. N Engl J Med 345, 1515–1521.

78.

Yip

, Green

, Huyck

, Cupples

, Farrer

, Mirage Study Group (2005) Nonsteroidal anti-inflammatory drug use and Alzheimer’s disease risk: The MIRAGE study. BMC Geriatr 5, 2.

79.

Wang

, Tan

, Wang

, Tan

, Meng

, Wang

, Tang

, Yu

(2015) Anti-inflammatory drugs and risk of Alzheimer’s disease: An updated systematic review and meta-analysis. J Alzheimers Dis 44, 385–396.

80.

Choi

, Carreras

, Aytan

, Jenkins-Sahlin

, Dedeoglu

, Jenkins

(2014) The effects of aging, housing and ibuprofen treatment on brain neurochemistry in a triple transgene Alzheimer’s disease mouse model using magnetic resonance spectroscopy and imaging. Brain Res 1590, 85–96 .

81.

Yan

, Zhang

, Liu

, Babu-Khan

, Vassar

, Biere

, Citron

, Landreth

(2003) Anti-inflammatory drug therapy alters beta-amyloid processing and deposition in an animal model of Alzheimer’s disease. J Neurosci 23, 7504–7509.

82.

Pasinetti

(2002) From epidemiology to therapeutic trials with anti-inflammatory drugs in Alzheimer’s disease: The role of NSAIDs and cyclooxygenase in beta-amyloidosis and clinical dementia. J Alzheimers Dis 4, 435–445.

83.

Szekely

, Zandi

(2010) Non-steroidal anti-inflammatory drugs and Alzheimer’s disease: The epidemiological evidence. CNS Neurol Disord Drug Targets 9, 132–139.

84.

ADAPT-FS Research Group (2015) Follow-up evaluation of cognitive function in the randomized Alzheimer’s Disease Anti-inflammatory Prevention Trial and its Follow-up Study. Alzheimers Dement 11, 216–225.

High-Throughput Screening for Identification of Blood-Brain Barrier Integrity Enhancers: A Drug Repurposing Opportunity to Rectify Vascular Amyloid Toxicity

Abstract

Keywords

INTRODUCTION

MATERIALS AND METHODS

Materials

Cell culture

Establishment of the BBB endothelium model for HTS

Permeability assay

bEnd3 cells growth assay

Model and assay validation

Quality control of the model

Compounds screening

Western blots analyses of tight junction protein claudin-5

Immunostaining of the tight junction claudin-5

Effect of hit FDA compounds on compromised bEnd3 cell-based BBB model by amyloid-β

Effect of hit FDA compounds on rectifying the disruptive effect of Aβ mixture in hCMEC/D3 cell-based BBB model

Statistical analysis

RESULTS

Coating optimization

Permeability, resistance, and growth assessment of bEnd3 monolayer

Model validation

Quality control of established model for HTS

Screening of LOPAC®1280 library

Effect of hit FDA-approved drugs on claudin-5 expression

Protective effect of hit FDA drugs against amyloid vascular toxicity in bEnd3 cells

Hit FDA drugs have deferential effect against amyloid vascular toxicity in hCMEC/D3 cells

DISCUSSION

Footnotes

ACKNOWLEDGMENTS

Appendix

References

Screening of LOPAC^®1280 library